Terns Pharmaceuticals Inc (TERN) Stock Price, Quote & News

Company Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 525 5535

Fax: 650 275 4254

Website: www.ternspharma.com

Address:

1065 East Hillsdale Boulevard, Suite 100, Foster City, United States

Whiskeyunderthebed Feb. 17 at 7:08 PM

$TERN First Turn Management, LLC disclosed a new position in Terns Pharmaceuticals (NASDAQ:TERN) in a February 13, 2026, SEC filing, acquiring 872,049 shares in an estimated $35.23 million trade.

0 · Reply

Gemola Feb. 17 at 6:04 PM

$TERN First target $42.50 boolish

0 · Reply

DragonAlgo Feb. 17 at 2:12 PM

🐉 $TERN PUT — DragonAlgo® Signal Contract: TERN PUT Expiry: 2026-02-20 | Strike: $33.00 | Type: PUT Option Plan (premium): Entry: $1.65 Stop: $1.19 TP1: $2.15 TP2: $2.80 TP3: $3.96 🔗 https://dragonalgo.com

0 · Reply

Brianum2011 Feb. 15 at 10:43 PM

$CRVS $TERN Better long term hold?

1 · Reply

Brianum2011 Feb. 15 at 1:43 PM

$IBRX $TERN $NKTR $PRAX

0 · Reply

BioRich Feb. 11 at 7:54 PM

$NVAX With last evening's confidence buy, NVAX is now up to #3 on my big board. Currently rankings: #1 - $GUTS #2 - $VNDA #3 - NVAX #4 - $MIST #5 - $TERN Feeling pretty good right about now.

4 · Reply

BillionerOfKing Feb. 6 at 11:48 AM

$TERN Current Stock Price: $35.33 Contracts to trade: $35.0 TERN Feb 20 2026 Call Entry: $3.78 Exit: $5.11 ROI: 35% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

TradeSun Feb. 5 at 7:02 PM

That's what I call a red, red day! $VKTX in trouble. $NVO and $LLY are discussed. $ALT & $TERN relatively strong.

1 · Reply

RMN1 Feb. 5 at 4:51 PM

$TERN

0 · Reply

CubicleTrader24 Feb. 5 at 2:33 AM

$TERN Re-test of the low after the trendline break looking interesting. Looking like it could be the 2 forming in a 1-2-3 reversal. Be interesting to see if this can get going again in the coming weeks.

0 · Reply

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Jan 22, 2026, 10:26 AM EST - 26 days ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 12, 2026, 9:15 PM EST - 5 weeks ago

Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 4:05 PM EST - 5 weeks ago

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 6:31 PM EST - 2 months ago

Terns CEO Amy Burroughs talks cancer drug trial win

Dec 11, 2025, 4:05 PM EST - 2 months ago

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 9, 2025, 11:30 PM EST - 2 months ago

Terns Announces Pricing of Upsized $650 Million Public Offering

Dec 9, 2025, 3:31 PM EST - 2 months ago

Cancer Study Buoys These Small Biotechs

ACLX LEGN

Dec 9, 2025, 2:34 PM EST - 2 months ago

Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again

Dec 9, 2025, 6:12 AM EST - 2 months ago

Terns Announces Proposed Public Offering

Dec 8, 2025, 11:27 PM EST - 2 months ago

Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript

$Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting$

Dec 8, 2025, 2:45 PM EST - 2 months ago

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Nov 14, 2025, 4:05 PM EST - 3 months ago

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Nov 10, 2025, 4:05 PM EST - 3 months ago

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 3, 2025, 1:05 PM EST - 3 months ago

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades

$Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting$

Nov 3, 2025, 9:05 AM EST - 3 months ago

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Oct 22, 2025, 2:43 PM EDT - 4 months ago

Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?

Oct 21, 2025, 4:56 PM EDT - 4 months ago

Terns Pharma ends obesity drug program after mid-stage trial data

Oct 21, 2025, 4:05 PM EDT - 4 months ago

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Sep 10, 2025, 12:13 PM EDT - 5 months ago

Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 11:33 PM EDT - 5 months ago

Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript

Aug 21, 2025, 4:05 PM EDT - 6 months ago

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Aug 5, 2025, 4:05 PM EDT - 6 months ago

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Jul 11, 2025, 11:27 AM EDT - 7 months ago

Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts

Jun 23, 2025, 4:07 PM EDT - 8 months ago

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

May 29, 2025, 4:05 PM EDT - 9 months ago

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 14, 2025, 9:30 AM EDT - 9 months ago

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 8, 2025, 4:05 PM EDT - 10 months ago

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 30, 2025, 4:05 PM EDT - 10 months ago

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Apr 2, 2025, 4:05 PM EDT - 11 months ago

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Mar 20, 2025, 4:05 PM EDT - 11 months ago

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Feb 26, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Feb 25, 2025, 8:05 AM EST - 1 year ago

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Feb 20, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Feb 5, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jan 8, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 1:18 PM EST - 1 year ago

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Dec 3, 2024, 8:01 AM EST - 1 year ago

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

AMRN SLN

Nov 18, 2024, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Nov 15, 2024, 11:19 AM EST - 1 year ago

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

AMGN LLY NVO VKTX

Sep 25, 2024, 10:30 AM EDT - 1 year ago

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Sep 13, 2024, 1:30 PM EDT - 1 year ago

Undercovered Stock Picks From September 6-12: Lithium, Uranium, Gold, & Plastic

ATLX BRZE DOCN EGO PL SLVM SMR

Sep 12, 2024, 7:00 PM EDT - 1 year ago

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 10, 2024, 10:50 PM EDT - 1 year ago

Terns Announces Pricing of Upsized $150.15 Million Public Offering

Sep 10, 2024, 10:25 AM EDT - 1 year ago

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Sep 9, 2024, 9:58 AM EDT - 1 year ago

Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill

Sep 9, 2024, 9:12 AM EDT - 1 year ago

Top 2 Health Care Stocks That May Collapse This Quarter

IMVT

Whiskeyunderthebed Feb. 17 at 7:08 PM

$TERN First Turn Management, LLC disclosed a new position in Terns Pharmaceuticals (NASDAQ:TERN) in a February 13, 2026, SEC filing, acquiring 872,049 shares in an estimated $35.23 million trade.

0 · Reply

Gemola Feb. 17 at 6:04 PM

$TERN First target $42.50 boolish

0 · Reply

DragonAlgo Feb. 17 at 2:12 PM

0 · Reply

Brianum2011 Feb. 15 at 10:43 PM

$CRVS $TERN Better long term hold?

1 · Reply

Brianum2011 Feb. 15 at 1:43 PM

$IBRX $TERN $NKTR $PRAX

0 · Reply

BioRich Feb. 11 at 7:54 PM

$NVAX With last evening's confidence buy, NVAX is now up to #3 on my big board. Currently rankings: #1 - $GUTS #2 - $VNDA #3 - NVAX #4 - $MIST #5 - $TERN Feeling pretty good right about now.

4 · Reply

BillionerOfKing Feb. 6 at 11:48 AM

0 · Reply

TradeSun Feb. 5 at 7:02 PM

That's what I call a red, red day! $VKTX in trouble. $NVO and $LLY are discussed. $ALT & $TERN relatively strong.

1 · Reply

RMN1 Feb. 5 at 4:51 PM

$TERN

0 · Reply

CubicleTrader24 Feb. 5 at 2:33 AM

0 · Reply

BioRich Feb. 4 at 6:02 PM

$TERN Worth re-sharing. Expecting a deal soon. Exciting times! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI

0 · Reply

RMN1 Feb. 4 at 3:30 PM

$TERN - Still great time for SHORT / Puts.. Act NOW and wait for some time ..

1 · Reply

masonat Feb. 4 at 3:07 PM

$TERN For some perspective, $NVS paid **10B** for Leqvio. Leqvio and Scemblix launched the same quarter. Scemblix has more revenue and is growing faster. Get it?

0 · Reply

TheRealShortSqueezy Feb. 4 at 1:04 PM

🚨 $MTVA : AI Analysis Strengthens The Case For Vanoglipel MetaVia is a Clinical stage biotech targeting cardiometabolic diseases such as obesity, fatty liver and diabetes. Today’s News! MetaVia reported new results from its AI collaboration with Syntekabio using the DeepMatcher platform. The AI modeled compound-protein interactions for vanoglipel and identified where the drug is biologically active. What the modeling showed: ➡️ Strong engagement of inflammatory pathways ➡️Alignment with cardiometabolic disease biology ➡️Supports development in MASH and Type 2 diabetes ➡️Cancer pathways also appeared due to inflammation reduction mechanisms It also matches earlier Phase 2a findings: ➡️Direct liver activity ➡️Improved glucose metabolism The AI data reinforces that vanoglipel’s biology makes sense and lowers scientific risk as development moves forward, especially for MASH and diabetes. Communicated Disclaimer: https://chartingdaily.com/metabolic-health Sector Peers: $GPCR $ALT $TERN $REGN

0 · Reply

masonat Feb. 4 at 11:56 AM

$TERN Scemblix sales up 85% to 1.3B. There won't be much of a point in using Scemblix in a few years with TERN701 on the market.

0 · Reply

twincam Feb. 3 at 5:02 PM

$TERN — Shares continuing higher with limited short-dated options activity. Call OI remains concentrated above spot while put demand is muted, suggesting the move is being driven by spot positioning rather than speculative call chasing.

0 · Reply